BR0113776A - Composição de pirrolocarbazóis selecionados fundidos e método para tratar e prevenir várias doenças usando a citada composição - Google Patents

Composição de pirrolocarbazóis selecionados fundidos e método para tratar e prevenir várias doenças usando a citada composição

Info

Publication number
BR0113776A
BR0113776A BR0113776-0A BR0113776A BR0113776A BR 0113776 A BR0113776 A BR 0113776A BR 0113776 A BR0113776 A BR 0113776A BR 0113776 A BR0113776 A BR 0113776A
Authority
BR
Brazil
Prior art keywords
composition
various diseases
treating
fused pyrrolocarbazoles
preventing various
Prior art date
Application number
BR0113776-0A
Other languages
English (en)
Inventor
Diane Gingrich
Robert L Hudkins
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of BR0113776A publication Critical patent/BR0113776A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

"COMPOSIçãO DE PIRROLOCARBAZóIS SELECIONADOS FUNDIDOS E MéTODO PARA TRATAR E PREVENIR VáRIAS DOENçAS USANDO A CITADA COMPOSIçãO". A presente invenção se relaciona geralmente com pirrolocarbazóis fundidos selecionados, incluindo composições farmacêuticas dos mesmos e métodos para tratar doenças com os mesmos. A presente invenção também é dirigida a intermediários e processos para produzir estes pirrolocarbazóis fundidos.
BR0113776-0A 2000-08-25 2001-08-23 Composição de pirrolocarbazóis selecionados fundidos e método para tratar e prevenir várias doenças usando a citada composição BR0113776A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22780300P 2000-08-25 2000-08-25
US27845501P 2001-03-23 2001-03-23
US09/935,285 US6630500B2 (en) 2000-08-25 2001-08-22 Selected fused pyrrolocarbazoles
PCT/US2001/026266 WO2002017914A2 (en) 2000-08-25 2001-08-23 Fused pyrrolocarbazoles against inflammation

Publications (1)

Publication Number Publication Date
BR0113776A true BR0113776A (pt) 2004-02-03

Family

ID=27397767

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113776-0A BR0113776A (pt) 2000-08-25 2001-08-23 Composição de pirrolocarbazóis selecionados fundidos e método para tratar e prevenir várias doenças usando a citada composição

Country Status (26)

Country Link
US (3) US6630500B2 (pt)
EP (1) EP1311263B1 (pt)
JP (1) JP5399598B2 (pt)
KR (1) KR100810190B1 (pt)
CN (1) CN1298323C (pt)
AR (1) AR034143A1 (pt)
AT (1) ATE306920T1 (pt)
AU (1) AU8520501A (pt)
BG (1) BG66103B1 (pt)
BR (1) BR0113776A (pt)
CA (1) CA2420592C (pt)
CZ (1) CZ303707B6 (pt)
DE (1) DE60114215T2 (pt)
DK (1) DK1311263T3 (pt)
EA (1) EA006371B1 (pt)
ES (1) ES2250463T3 (pt)
HK (1) HK1053989A1 (pt)
HU (1) HU230128B1 (pt)
IL (2) IL154590A0 (pt)
MX (1) MXPA03001562A (pt)
NO (1) NO325689B1 (pt)
NZ (1) NZ524288A (pt)
PL (1) PL212956B1 (pt)
SK (1) SK287498B6 (pt)
TW (1) TWI299731B (pt)
WO (1) WO2002017914A2 (pt)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
NZ539101A (en) 2002-10-08 2008-08-29 Rinat Neuroscience Corp Methods for treating post-surgical pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
EP1575517B1 (en) 2002-12-24 2012-04-11 Rinat Neuroscience Corp. Anti-ngf antibodies and methods using same
MXPA05008815A (es) 2003-02-19 2006-05-25 Rinat Neuroscience Corp Metodos para tratar el dolor al administrar un antagonista del factor de crecimiento de nervios y un farmaco antiinflamatorio no esteroidal y composiciones que contienen los mismos.
KR101254371B1 (ko) 2003-07-18 2013-05-02 암젠 프레몬트 인코포레이티드 간세포 성장인자에 결합하는 분리된 항체
US7169802B2 (en) 2003-12-23 2007-01-30 Cephalon, Inc. Fused pyrrolocarbazoles
US7241779B2 (en) * 2003-12-23 2007-07-10 Cephalon, Inc. Fused pyrrolocarbazoles
CA2562024C (en) 2004-04-07 2014-05-27 Rinat Neuroscience Corp. Methods for treating bone cancer pain by administering a nerve growth factor antagonist
US7652009B2 (en) 2004-11-30 2010-01-26 Amgem Inc. Substituted heterocycles and methods of use
US20060134175A1 (en) * 2004-12-22 2006-06-22 Stephen Bartels Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use
US20060134176A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
US20060134174A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
US20060216288A1 (en) * 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
US20060293378A1 (en) * 2005-06-28 2006-12-28 Mcintire Gregory Method of lowering intraocular pressure
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
CA2672438A1 (en) 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
WO2008086014A2 (en) 2007-01-09 2008-07-17 Amgen Inc. Bis-aryl amide derivatives useful for the treatment of cancer
AU2008219166B2 (en) 2007-02-16 2013-05-16 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
EP2167075A4 (en) * 2007-06-08 2012-07-11 Univ Massachusetts MIXED LINEAGE KINASES AND METABOLISM DISORDER
PT2188313T (pt) 2007-08-21 2017-12-12 Amgen Inc Proteínas de ligação ao antigénio c-fms humano
MX2011005055A (es) * 2008-11-19 2011-05-31 Cephalon Inc Nuevas formas de un compuesto de indazolo [5,4-a]pirrolo[3,4-c]car bazol.
EP2192121A1 (en) 2008-11-27 2010-06-02 Cephalon France Regioselective reduction of fused pyrrolocarbazoles-5,7-diones
KR101038055B1 (ko) * 2010-06-10 2011-06-01 송광섭 수중 마사지장치
WO2011161217A2 (en) 2010-06-23 2011-12-29 Palacký University in Olomouc Targeting of vegfr2
EP2937349B1 (en) 2011-03-23 2016-12-28 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
WO2013025939A2 (en) 2011-08-16 2013-02-21 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US9505749B2 (en) 2012-08-29 2016-11-29 Amgen Inc. Quinazolinone compounds and derivatives thereof
JP7041515B2 (ja) 2015-01-08 2022-03-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 骨、骨髄、及び軟骨の誘導を提供する因子及び細胞
CR20190338A (es) 2016-12-22 2019-09-09 Amgen Inc Inhibidores de kras g12c y métodos para su uso
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
CN116003405A (zh) 2017-09-08 2023-04-25 美国安进公司 Kras g12c的抑制剂及其使用方法
MX2020010836A (es) 2018-05-04 2021-01-08 Amgen Inc Inhibidores de kras g12c y métodos para su uso.
WO2019213526A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
CA3099045A1 (en) 2018-05-10 2019-11-14 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
EP3802535B1 (en) 2018-06-01 2022-12-14 Amgen, Inc Kras g12c inhibitors and methods of using the same
WO2019241157A1 (en) 2018-06-11 2019-12-19 Amgen Inc. Kras g12c inhibitors for treating cancer
MX2020012261A (es) 2018-06-12 2021-03-31 Amgen Inc Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
US11053226B2 (en) 2018-11-19 2021-07-06 Amgen Inc. KRAS G12C inhibitors and methods of using the same
MX2021007104A (es) 2018-12-20 2021-08-11 Amgen Inc Inhibidores de kif18a.
WO2020132653A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
JP2022513967A (ja) 2018-12-20 2022-02-09 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
AR117490A1 (es) 2018-12-20 2021-08-11 Amgen Inc Inhibidores de kif18a
KR20210146288A (ko) 2019-03-01 2021-12-03 레볼루션 메디슨즈, 인크. 이환식 헤테로사이클릴 화합물 및 이의 용도
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
CA3140392A1 (en) 2019-05-21 2020-11-26 Amgen Inc. Solid state forms
MX2022001302A (es) 2019-08-02 2022-03-02 Amgen Inc Inhibidores de kif18a.
EP4007756A1 (en) 2019-08-02 2022-06-08 Amgen Inc. Kif18a inhibitors
MX2022001296A (es) 2019-08-02 2022-02-22 Amgen Inc Inhibidores de kif18a.
JP2022542967A (ja) 2019-08-02 2022-10-07 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤
EP4048671A1 (en) 2019-10-24 2022-08-31 Amgen Inc. Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
MX2022005357A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
CA3159561A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
CR20220243A (es) 2019-11-04 2022-08-04 Revolution Medicines Inc Inhibidores de ras
BR112022008858A2 (pt) 2019-11-08 2022-09-06 Revolution Medicines Inc Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
US20230192682A1 (en) 2019-11-14 2023-06-22 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
IL292315A (en) 2019-11-14 2022-06-01 Amgen Inc Improved synthesis of a kras g12c inhibitory compound
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
BR112022010086A2 (pt) 2020-01-07 2022-09-06 Revolution Medicines Inc Dosagem do inibidor de shp2 e métodos de tratamento de câncer
IL299131A (en) 2020-06-18 2023-02-01 Revolution Medicines Inc Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
AU2021344830A1 (en) 2020-09-03 2023-04-06 Revolution Medicines, Inc. Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
CN116457358A (zh) 2020-09-15 2023-07-18 锐新医药公司 作为ras抑制剂以治疗癌症的吲哚衍生物
EP4267250A1 (en) 2020-12-22 2023-11-01 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
IL308195A (en) 2021-05-05 2024-01-01 Revolution Medicines Inc RAS inhibitors for cancer treatment
EP4334324A1 (en) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
CN118234731A (zh) 2021-05-05 2024-06-21 锐新医药公司 Ras抑制剂
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
TW202340214A (zh) 2021-12-17 2023-10-16 美商健臻公司 做為shp2抑制劑之吡唑并吡𠯤化合物
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
US20230348608A1 (en) 2022-04-27 2023-11-02 Regeneron Pharmaceuticals, Inc. Treatment Of Arthropathy Based Upon Stratification Of Osteoarthritis Polygenic Risk Score
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024081916A1 (en) 2022-10-14 2024-04-18 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552842A (en) 1983-01-28 1985-11-12 Bristol-Myers Company Process for producing rebeccamycin
US5438050A (en) 1988-02-06 1995-08-01 Godecke Aktiengesellschaft Indolocarbazole derivatives, processes for their preparation and compositions containing them
US5185260A (en) 1991-08-29 1993-02-09 The United States Of America As Represented By The United States Department Of Energy Method for distinguishing normal and transformed cells using G1 kinase inhibitors
US5475110A (en) 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5705511A (en) 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5594009A (en) 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5591855A (en) 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5705711A (en) * 1995-08-17 1998-01-06 Huntsman Specialty Chemicals Corporation Manufacture of methyl tertiary butyl ether in reactive distillation column
US5808060A (en) 1995-12-11 1998-09-15 Cephalon, Inc. Fused isoindolones
US5616724A (en) 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
RU2167880C2 (ru) 1996-08-22 2001-05-27 Бристол-Маерс Сквибб Компани Индолопирролокарбазольные производные сахаров, содержащая их фармацевтическая композиция и способ ингибирования роста опухолей
US6127401A (en) 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
DE69936059T2 (de) 1998-09-25 2008-01-24 Cephalon, Inc. Methoden zur prophylaxe und behandlung von schäden der wahrnehmungshärchenzellen und der cochlearen neuronen
US6841567B1 (en) 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones

Also Published As

Publication number Publication date
DK1311263T3 (da) 2006-02-13
JP5399598B2 (ja) 2014-01-29
WO2002017914A3 (en) 2002-04-18
NO20030845D0 (no) 2003-02-24
US20060135590A1 (en) 2006-06-22
AU8520501A (en) 2002-03-13
CZ303707B6 (cs) 2013-03-27
AR034143A1 (es) 2004-02-04
WO2002017914A8 (en) 2002-07-11
EA006371B1 (ru) 2005-12-29
EA200300293A1 (ru) 2003-08-28
PL365683A1 (en) 2005-01-10
US6630500B2 (en) 2003-10-07
SK287498B6 (sk) 2010-12-07
ES2250463T3 (es) 2006-04-16
DE60114215T2 (de) 2006-07-13
ATE306920T1 (de) 2005-11-15
TWI299731B (en) 2008-08-11
IL191104A0 (en) 2008-11-03
BG107659A (bg) 2004-01-30
CN1298323C (zh) 2007-02-07
US7115613B2 (en) 2006-10-03
NZ524288A (en) 2005-04-29
CA2420592A1 (en) 2002-03-07
EP1311263A2 (en) 2003-05-21
KR20030036727A (ko) 2003-05-09
US20020061920A1 (en) 2002-05-23
HK1053989A1 (en) 2003-11-14
CN1449287A (zh) 2003-10-15
NO325689B1 (no) 2008-07-07
CZ2003539A3 (cs) 2003-10-15
PL212956B1 (pl) 2012-12-31
HU230128B1 (hu) 2015-08-28
US20030203957A1 (en) 2003-10-30
WO2002017914A2 (en) 2002-03-07
SK2192003A3 (en) 2003-11-04
MXPA03001562A (es) 2004-12-13
KR100810190B1 (ko) 2008-03-06
CA2420592C (en) 2011-01-11
IL154590A0 (en) 2003-09-17
BG66103B1 (bg) 2011-04-29
HUP0303103A3 (en) 2004-11-29
DE60114215D1 (de) 2006-03-02
NO20030845L (no) 2003-04-16
HUP0303103A2 (hu) 2003-12-29
JP2004507500A (ja) 2004-03-11
EP1311263B1 (en) 2005-10-19
US7230026B2 (en) 2007-06-12

Similar Documents

Publication Publication Date Title
BR0113776A (pt) Composição de pirrolocarbazóis selecionados fundidos e método para tratar e prevenir várias doenças usando a citada composição
UY26813A1 (es) Compuestos para tratar enfermedad de alzheimer
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
BR9808953A (pt) Composto, processo para tratar um distúrbio mediado pela ciclooxigenase-2 em um paciente, e, composição farmacêutica
WO2002002506A3 (en) Compounds to treat alzheimer's disease
BR9813767A (pt) Processo e composição para tratar glaucoma de glc1a
BG106685A (en) Using of fumaric acid derivatives for treating mitochondrial diseases
HUP0303022A2 (hu) Kinazolin-ditozilátsó vegyületek, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
BRPI0111116B8 (pt) imitadores de trombopoietina
CY1112932T1 (el) Αναστολεις sμαd7 για τη θεραπευτικη αγωγη ασθενειων του κνς
WO2002002520A3 (en) Compounds to treat alzheimer's disease
BR0108600A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, métodos para tratamento de uma doença mediada por quimiocina e para tratamento de uma doença inflamatória
BRPI0113162B8 (pt) compostos ariloxialquilaminas nao-imidazólicos e composição farmacêutica compreendendo os referidos compostos
BRPI0417376A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades que estão associadas com a modulação de receptores de cb1 e sua utilização
BR0211118A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
EA200001085A1 (ru) 5-аминоиндено [1, 2-с]пиразол-4-оны в качестве противораковых и антипролиферативных агентов
LV12291A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BRPI0418120A (pt) composto, composição farmacêutica, e, métodos para tratar um distúrbio, uma doença ou distúrbio, e para tratar mieloma múltiplo ou leucemia
DE60219614D1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
NO995843D0 (no) Farmasöytisk preparat omfattende vWF-propeptid
BR0208405A (pt) Compostos de diidropirimina substituìdos com ciano e seu uso para tratar doenças
BR0213417A (pt) Compostos e composições de tetraciclicazaindóis e indolinas tendo atividade de 5-ht e seus usos
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
BR9911559A (pt) Processo para a preparação de um composto, composto, processo para o tratamento de tumores resistentes a medicamento múltiplo, uso de um composto, e, agente e composição para tratar tumores resistentes a medicamento múltiplo.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: DE ACORDO COM ART. 34 " II " DA LPI ( LEI 9279, DE 14/05/96 ) , O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO.

B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]